|
|
Brown Medical School
HIV 101: HIV Vaccine Candidates
By HEPP News Staff
October 2001
Adapted from Johnston M.I., Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology . 2001:1(5):504-520. On the Web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf. Additional information from Science Magazine 2001 293 (5537): 1973.
As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides information on vaccines currently in the development pipeline.
Vaccine Name | HIV Subtype Targeted | Producing Company | Status |
| gp120 | B/B, B/E | VaxGen | Ongoing phase III trials in the United States and Thailand |
| ALVAC-HIV | B, E | Aventis Pasteur | Ongoing phase II trials in the U.S., Haiti, Brazil, Trinidad (subtype B); Thailand (sub-type E); used alone or in combination with gp120 |
| ALVAC-HIV | A | Aventis Pasteur | Ready for Phase I trials in Uganda |
| Lipopeptides LP5, LP6 | B | ANRS: National Agency for AIDS Research, France | Ongoing phase I trials in France |
| Vaccinia TBC-3B | B | Therion | Ongoing phase I trials in the U.S. |
| DNA-HIV | B | Apolion | Completed phase I trials |
| DNA-HIV, MVA-HIV | A | University of Oxford | Ongoing phase I trials in the UK and Kenya |
| NYVAC-HIV | B | Aventis Pasteur | Ready for phase I in the U.S. |
| DNA-HIV, Adenovirus HIV | B | Merck | Ongoing phase I trials in the U.S. |
| VaxGen Canarypox with HIV gag, protease, and env +gp120 | B/E | U.S. Military, Royal Thai Govt., Mahidol U., Aventis Pasteur, VaxGen | Earliest phase III start date: Summer 2002, Thailand* |
| Canarypox with HIV env, gag, protease, pol, and nef, +gp120 | B/? | NIH HVTN, Aventis Pasteur, VaxGen | Earliest phase III start date: December 2002, U.S., Brazil, Haiti, Peru, Trinidad (Possible: Argentina, Dominican Republic, Honduras)* |
|
* Proposed AIDS vaccine efficacy trials (see "News Flashes").
phase I trial: first stage trial, focusing on safety and toxicity, very small cohort.
phase II trial: second stage trial, measures efficacy of vaccine in small cohort.
phase III trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale.
gp120: recombinant HIV envelope protein.
ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes.
MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes.
NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes.
TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes.
|
Back to the HEPP News October 2001 contents page.
This article was provided by Brown Medical School. It is a part of the publication HEPP News.
|
|
